Literature DB >> 16682254

Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver.

Peter Bell1, A David Moscioni, Robert J McCarter, Di Wu, Guangping Gao, Albert Hoang, Julio C Sanmiguel, Xun Sun, Nelson A Wivel, Steven E Raper, Emma E Furth, Mark L Batshaw, James M Wilson.   

Abstract

The present study reports on the frequency of liver tumors observed in a gene therapy study with AAV vectors in male mice of the B6C3F1 hybrid background, which are known to have a high frequency of spontaneous liver tumors. Male mice with mutations in their Otc gene and their wild-type siblings received AAV vectors expressing either the murine Otc or the LacZ gene. Untreated control animals were included in the study. All experimental groups, including wild-type and OTC-deficient animals not treated with vector, developed liver nodules, which in some cases were due to hepatocellular carcinoma. Vector DNA was lower in tumors than in adjacent normal liver. A statistical analysis of the data did not show an association between treatment with Otc vectors and formation of tumors in OTC-deficient mice. However, mice treated with LacZ vectors showed increased risks of tumor formation and hepatocellular carcinoma relative to untreated animals or animals that had received vectors with Otc as the transgene. It appears that AAV vectors alone do not contribute to the formation of tumors in these strains of mice although the expression of LacZ alone or in combination with vector may be problematic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682254     DOI: 10.1016/j.ymthe.2006.03.008

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  59 in total

1.  Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector.

Authors:  Lili Wang; Huan Wang; Peter Bell; Deirdre McMenamin; James M Wilson
Journal:  Hum Gene Ther       Date:  2012-02-08       Impact factor: 5.695

2.  AAV provides an alternative for gene therapy of the peripheral sensory nervous system.

Authors:  Andreas S Beutler
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

3.  Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?

Authors:  Kenneth I Berns; Barry J Byrne; Terence R Flotte; Guangping Gao; William W Hauswirth; Roland W Herzog; Nicholas Muzyczka; Thierry VandenDriessche; Xiao Xiao; Sergei Zolotukhin; Arun Srivastava
Journal:  Hum Gene Ther       Date:  2015-12       Impact factor: 5.695

Review 4.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

5.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

Authors:  Glenn P Niemeyer; Roland W Herzog; Jane Mount; Valder R Arruda; D Michael Tillson; John Hathcock; Frederik W van Ginkel; Katherine A High; Clinton D Lothrop
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

6.  AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta).

Authors:  Lili Wang; Peter Bell; Jianping Lin; Roberto Calcedo; Alice F Tarantal; James M Wilson
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

7.  The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.

Authors:  Lili Wang; Roberto Calcedo; Huan Wang; Peter Bell; Rebecca Grant; Luk H Vandenberghe; Julio Sanmiguel; Hiroki Morizono; Mark L Batshaw; James M Wilson
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

8.  Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors.

Authors:  Lili Wang; Roberto Calcedo; Peter Bell; Jianping Lin; Rebecca L Grant; Don L Siegel; James M Wilson
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

9.  Transfection of cells using flow-through electroporation based on constant voltage.

Authors:  Tao Geng; Yihong Zhan; Jun Wang; Chang Lu
Journal:  Nat Protoc       Date:  2011-07-21       Impact factor: 13.491

Review 10.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.